Print Page  |  Contact Us  |  Sign In  |  Join ACAM
News & Press: Member News

ACAM Member Dr. Dana Cohen selected as official TACT II Trail Site

Friday, December 16, 2016   (0 Comments)
Posted by: Administration
Share |

Second study will focus on benefits of removing toxic metal pollutants in patients with diabetes and a prior heart attack

Dana G. Cohen, MD has been named a participating clinical site for the second Trial to Assess Chelation Therapy (TACT2). TACT2 will examine the use of intravenous chelation treatments in combination with oral vitamins in diabetic patients with a prior heart attack to determine if they reduce recurrent heart episodes, such as heart attacks, stroke, death, and others, by removing toxins from the blood. READ MORE

Community Search
Sign In
Sign In securely

9/14/2017 » 9/16/2017
ACAM 2017 Annual Meeting

Latest News